Tivic Health Advances its Vagus Nerve Stimulation Commercial Strategy

Tivic Health Systems Inc. is partnering with Fletcher Spaght (FSI) to accelerate the development of its commercial strategy for non-invasive cervical vagus nerve stimulation (ncVNS).
 
Polaris Market Research estimates the global vagus nerve stimulation market will expand 10.6% annually through 2030, going from $8.59 billion in 2021 to $21.3 billion in 2030. Additionally, IDTechEx has forecast peripheral nerve stimulation, the segment targeted by Tivic Health, will grow 35% annually, one of the fastest growth segments in bioelectronic medicine.
 
“FSI excels at projects like this, where our insights help clients like Tivic grow while improving patient healthcare. Bringing innovative technologies like ncVNS to market drives us, and we’re excited to support Tivic’s journey in advancing care across multiple therapeutic areas,” FSI Partner Bill Sigona stated. 
 
The firm has begun a comprehensive market assessment of Tivic Health’s ncVNS technology drawing from clinical outcomes from Tivic Health’s Phase 1 trial. Fletcher Spaght initially identified approximately 30 potential medical use cases for Tivic Health’s ncVNS technology in neurologic, cardiac, psychiatric and autonomic nervous system diseases. The firm is now working closely with Tivic Health’s scientific and clinical leadership to identify the strongest market entry point by interviewing clinical key opinion leaders, patients and payers.
 
“The work with Fletcher Spaght will help us sharpen our go-to-market strategy, clinical study plans, reimbursement pathway, and product development pipeline for our vagus nerve stimulation program,” Tivic Health CEO Jennifer Ernst explained. “The early outcomes from the engagement confirm there are significant market opportunities for our novel non-invasive bioelectronic therapies.”
 
Tivic Health has previously announced the successful completion of a Phase 1 trial, in which the company’s ncVNS produced strong physiological effects in neurological, cardiac, and autonomic systems. Tivic Health engaged Fletcher Spaght to help evaluate and prioritize clinical use cases for Tivic’s ncVNS platform. The company expects to derive insights that will drive the company’s clinical strategy and product development in 2025 and beyond.
 
Tivic Health is a commercial health tech company advancing bioelectronic medicine. Its technology platforms leverage stimulation of the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to treating inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is a U.S. Food and Drug Administration-approved handheld bioelectronic sinus device. 
 
Fletcher Spaght is renowned for its analytical rigor and operational expertise, FSI crafts effective growth strategies for a wide range of clients, including major healthcare corporations, private equity firms, and innovative startups. With thousands of successful engagements, FSI has played a key role in launching numerous companies, facilitating hundreds of strategic transactions, and managing more than $130 million in venture capital investments.